The company has no plans for additional studies of Zofran in alcoholism. Data from an investigator-initiated NIH trial of the anti-emetic ondansetron for the treatment of early-onset alcoholism was published in the Aug. 23 Journal of the American Medical Association. Glaxo issued a three page "fact sheet" coinciding with the JAMA publication, emphasizing that Zofran is not indicated for alcoholism. The investigator is planning a five-year study of 320 patients at the University of Texas Health Science Center, San Antonio. The alcoholism trials are using a very low dose of Zofran (4 mcg/kg) compounded from Glaxo's marketed tablets
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth